Technical and Regulatory Considerations for Taking Liquid Biopsy to the Clinic: Validation of the JAX PlasmaMonitor TM Assay
Authors:
Open Access
- 1 January 2019
- journal article
- research article
- Published by SAGE Publications in Biomarker Insights
- Vol. 14
Abstract
The standard of care in oncology has been genomic profiling of tumor tissue biopsies for the treatment and management of disease, which can prove to be quite challenging in terms of cost, invasiveness of procedure, and potential risk for the patient. As the number of available drugs in oncology continues to increase, so too does the demand for technologies and testing applications that can identify genomic alterations targetable by these new therapies. Liquid biopsies that use a blood draw from the diseased patient may offset the many disadvantages of the invasive procedure. However, as with any new technology or finding in the clinical field, the clinical utility of an analytical test such as that of the liquid biopsy has to be established. Here, we review the clinical testing space for liquid biopsy offerings and elucidate the technical and regulatory considerations to develop such an assay, using our recently validated PlasmaMonitor TM test.Keywords
This publication has 39 references indexed in Scilit:
- Detection of Circulating Tumor DNA in Early- and Late-Stage Human MalignanciesScience Translational Medicine, 2014
- Identification of Double-stranded Genomic DNA Spanning All Chromosomes with Mutated KRAS and p53 DNA in the Serum Exosomes of Patients with Pancreatic CancerJournal of Biological Chemistry, 2014
- A stabilizing reagent prevents cell-free DNA contamination by cellular DNA in plasma during blood sample storage and shipping as determined by digital PCRClinical Biochemistry, 2013
- Circulating cell free DNA: Preanalytical considerationsClinica Chimica Acta, 2013
- ACMG clinical laboratory standards for next-generation sequencingGenetics in Medicine, 2013
- Liquid biopsy: monitoring cancer-genetics in the bloodNature Reviews Clinical Oncology, 2013
- Circulating Tumor Cells: Liquid Biopsy of CancerClinical Chemistry, 2013
- Influence of Chemotherapy on EGFR Mutation Status Among Patients With Non–Small-Cell Lung CancerJournal of Clinical Oncology, 2012
- Circulating mutant DNA to assess tumor dynamicsNature Medicine, 2008
- Detection, clinical relevance and specific biological properties of disseminating tumour cellsNature Reviews Cancer, 2008